Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study.

Cancer discovery - 2 Sept 2022

Savas Peter, Lo Louisa L, Luen Stephen J, Blackley Elizabeth F, Callahan Jason, Moodie Kate, van Geelen Courtney T, Ko Yi-An, Weng Chen-Fang, Wein Lironne, Silva Maria João, Bujak Andjelija Zivanovic, Yeung Miriam M, Ftouni Sarah, Hicks Rodney J, Francis Prudence A, Lee Chee Khoon, Dawson Sarah-Jane, Loi Sherene

Abstract excerpt

There is limited knowledge on the benefit of the α-subunit-specific PI3K inhibitor alpelisib in later lines of therapy for advanced estrogen receptor-positive (ER+) HER2- and triple-negative breast cancer (TNBC). We conducted a phase II multicohort study of alpelisib monotherapy in patients with advanced PI3K pathway mutant ER+HER2- and TNBC. In the intention-to-treat ER+ cohort, the overall response rate was 30%...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Phosphatidylinositol 3-Kinases

Share to PI3K/AKT/mTOR signaling in cancer

Share to Receptor, ErbB-2

Share to Thiazoles

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 35771551
DOI: 10.1158/2159-8290.CD-21-1696

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study.PMID 35771551Read ↗

A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.Semantic proximity Read ↗

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.Semantic proximity Read ↗

Efficacy of PI3K inhibitors in advanced breast cancer.Semantic proximity Read ↗

Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.Semantic proximity Read ↗

Alpelisib to treat breast cancer.Semantic proximity Read ↗

Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access programSemantic proximity Read ↗

The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancerSemantic proximity Read ↗

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitorsSemantic proximity Read ↗

Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations.Semantic proximity Read ↗

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.Semantic proximity Read ↗

A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer.Semantic proximity Read ↗

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.